SLC18A2 and Parkinson disease: Ex vivo (OBCs) VMAT2 blockage with reserpine inhibits DA and glutamatergic synaptic activity in the prefrontal cortex, hippocampus, and VTA, key cognitive and affective nuclei involved in prodromal and late PD symptoms.